A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
about
Improved high sensitivity screen for Huntington disease using a one-step triplet-primed PCR and melting curve assay.Therapeutic advances in Huntington's Disease.Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.The effects of methylphenidate on resting-state striatal, thalamic and global functional connectivity in healthy adultsThe sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington diseaseThe effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.Investigational drugs for the management of Huntington's disease: are we there yet?Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.Diagnosis and treatment of chorea syndromes.Dopamine and Huntington's disease.The promise of futility trials in neurological diseases.Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature.Pridopidine for the treatment of Huntington's disease.Antipsychotic drugs in Huntington's disease.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Investigational agents for the management of Huntington's disease.Huntington's Disease-Update on Treatments.Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.Pridopidine activates neuroprotective pathways impaired in Huntington Disease.The pridopidine paradox in Huntington's disease.Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study.Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.Neuroprotective Effect of σ1-Receptors on the Cell Model of Huntington's Disease.Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Treatment options for chorea.The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.Pridopidine Reverses Phencyclidine-Induced Memory Impairment.Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Therapy development in Huntington disease: From current strategies to emerging opportunities.Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.Huntington disease
P2860
Q33897905-2354AB08-645E-41A4-A107-561B4C6EE0C1Q34487604-39736B28-F188-4FD8-8719-992E53FF9E52Q34547558-776E7B98-D805-42A8-B212-7A5100A6C0FEQ35864146-F04858ED-4812-494A-988C-2E0532F68ACBQ36183832-A3F3E035-3A0B-4A60-AABE-6D71D87DFAB8Q36802073-7C6190D2-898F-4E4A-BF7D-38BC06ED70A9Q38236052-8A336FFD-CFF6-4A24-A2DE-8767957B91C5Q38248689-5DBD55A9-C95C-4527-B64B-4D7F3134A4B9Q38332316-FF11D54A-CAF2-4823-8350-BCD6716D71F3Q38379277-A84C9177-402B-4981-B4B1-C7D85DDFFC5CQ38380170-FB797C7D-6004-4D18-AE31-F8B6715C2361Q38624994-195EFA9C-13B2-4A91-8B56-426900611B48Q38735562-35D62C27-E749-4C5C-89A2-D8CE66368804Q38830416-771BE143-C93B-4593-9DAA-E28E04AB95D7Q38861728-C5935E47-E6E3-46B9-B4A9-53D2AE5C3B9EQ39031769-8B777ACF-296B-4DC9-969C-7126B1CE910DQ39190617-B85C2F8C-69FE-4779-85C3-B285C7BE15AFQ40277912-B0852EB0-6C5A-4EEC-8E54-0677EBB751D4Q40753593-0F0A8082-52E4-4E23-B06E-BD18AF939552Q41196024-63AF77B4-93B3-40F7-9041-8BF972F2C94DQ42324179-5B84862A-61E4-4F2C-94B5-A91FA3E40B8DQ45294030-338B48D2-10FD-4FF4-8F9E-A27793A235DEQ45301837-C804C878-C20D-4335-9F55-3007C871BC18Q45305483-8C77AB94-C5B8-4F38-9961-E339FFC097A1Q47410169-A0B6D982-DCE4-48FD-9973-E89272979C31Q47694898-134D47C5-FF84-4EFA-891C-F3E5A067FF17Q47977953-5CCB9832-FA34-44B5-B1C6-A8D95B94E082Q51088282-0F5511DF-BF2C-43DA-A5CC-4AEF29FBA719Q52564664-9A3185CE-090E-4FA1-9E55-937866DCAEDBQ52685691-0A172866-BD86-4F3F-AD78-43918652404FQ53716390-FE0608B6-BEF5-454B-87BF-7DE409AD5C6EQ55335504-38D414FC-9648-4E3F-9B3E-0461F13E0DD6Q56083219-6D7A520A-E0AE-4E60-A098-F43412058E58
P2860
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... idine in Huntington's disease.
@en
A randomized, double-blind, pl ...... idine in Huntington's disease.
@nl
type
label
A randomized, double-blind, pl ...... idine in Huntington's disease.
@en
A randomized, double-blind, pl ...... idine in Huntington's disease.
@nl
prefLabel
A randomized, double-blind, pl ...... idine in Huntington's disease.
@en
A randomized, double-blind, pl ...... idine in Huntington's disease.
@nl
P2860
P356
P1433
P1476
A randomized, double-blind, pl ...... idine in Huntington's disease.
@en
P2093
Huntington Study Group HART Investigators
P2860
P304
P356
10.1002/MDS.25362
P407
P577
2013-02-28T00:00:00Z